A fixed-ratio combination of cagrilintide, a long-acting amylin analogue, with semaglutide, studied in the REDEFINE programme. Questions here concern the amylin contribution, why a co-formulation is not the same as two injections, and how to read a combination trial.
The receptor pharmacology I can follow; the in vivo translation is where I lose the thread. I would like help reading this properly rather than being told what…
I would like to know how much of this is established and how much is a reasonable story. I would like the mechanism, because I want to be able to reason about the…
I am asking mechanistically rather than practically — I want the model, not the protocol. This is presented as though it settles something, and I am not convinced it…
This matters because it predicts what a related molecule should do. I would like the axes of comparison first and the recommendation second. I have tried the first…
REDEFINE 1 reported mean weight loss of about 22.7% for CagriSema at 68 weeks, which as far as I can tell is the largest figure any phase 3 obesity trial has…
I am asking mechanistically rather than practically — I want the model, not the protocol. I can predict the outcome but I cannot explain it, which means I will get…
I am asking mechanistically rather than practically — I want the model, not the protocol. The comparison I want does not seem to exist anywhere in a form I can…
I have read the medicinal chemistry paper and the pharmacology paper, which helped and did not finish the job. I understand the observation; what I do not understand…
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse results